oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results
Örebro University, School of Health and Medical Sciences, Örebro University, Sweden. Endocrine and Diabetes Centre, Karlstad Hospital, Karlstad, Sweden; Örebro University Hospital, Örebro, Sweden.ORCID iD: 0000-0003-1025-1682
Center for Primary Health Care Research, University Hospital of Skåne, Lund, Sweden.
Department of Endocrinology, Skåne University Hospital, Lund, Sweden; Department of Clinical Sciences, Lund University, Malmö, Sweden.
Novo Nordisk Scandinavia, Malmö, Sweden.
Show others and affiliations
2012 (English)In: Journal of Medical Economics, ISSN 1369-6998, E-ISSN 1941-837X, Vol. 15, no Suppl 2, p. 1-5Article in journal (Refereed) Published
Abstract [en]

Objective: The purpose of this study was to investigate the preferences of people with diabetes for liraglutide vs other glucose lowering drugs, based on outcomes of clinical trials.

Methods: Willingness to pay (WTP) for diabetes drug treatment was assessed by combining results from a recent WTP study with analysis of results from the Liraglutide Effect and Action in Diabetes (LEAD) programme. The LEAD programme included six randomised clinical trials with 3967 participants analysing efficacy and safety of liraglutide 1.2 mg (LEAD 1-6 trials), rosiglitazone (LEAD 1 trial), glimepiride (LEAD 2-3 trials), insulin glargine (LEAD 5 trial), and exenatide (LEAD 6 trial). The WTP survey used discrete choice experimental (DCE) methodology to evaluate the convenience and clinical effects of glucose lowering treatments.

Results: People with type 2 diabetes were prepared to pay an extra €2.64/day for liraglutide compared with rosiglitazone, an extra €1.94/day compared with glimepiride, an extra €3.36/day compared with insulin glargine, and an extra €0.81/day compared with exenatide. Weight loss was the largest component of WTP for liraglutide compared with rosiglitazone, glimepiride, and insulin glargine. Differences in the administration of the two drugs was the largest component of WTP for liraglutide (once daily anytime) compared with exenatide (twice daily with meals). A limitation of the study was that it was based on six clinical trials where liraglutide was the test drug, but each trial had a different comparator, therefore the clinical effects of liraglutide were much better documented than the comparators.

Conclusions: WTP analyses of the clinical results from the LEAD programme suggested that participants with type 2 diabetes were willing to pay appreciably more for liraglutide than other glucose lowering treatments. This was driven by the relative advantage of weight loss compared with rosiglitazone, glimepiride, and insulin glargine, and administration frequency compared with exenatide.

Place, publisher, year, edition, pages
Oxfordshire, United Kingdom: Taylor & Francis, 2012. Vol. 15, no Suppl 2, p. 1-5
National Category
Clinical Medicine Endocrinology and Diabetes
Research subject
Medicine
Identifiers
URN: urn:nbn:se:oru:diva-27385DOI: 10.3111/13696998.2012.703633PubMedID: 22853443Scopus ID: 2-s2.0-84867939081OAI: oai:DiVA.org:oru-27385DiVA, id: diva2:603616
Available from: 2013-02-06 Created: 2013-02-06 Last updated: 2017-12-06Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Jendle, Johan

Search in DiVA

By author/editor
Jendle, Johan
By organisation
School of Health and Medical Sciences, Örebro University, Sweden
In the same journal
Journal of Medical Economics
Clinical MedicineEndocrinology and Diabetes

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 334 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf